AMICUS THERAPEUTICS, INC.
amicusrx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2025 10-K, filed Feb 20, 2026. Its latest SEC filing is a SCHEDULE 13G/A from Aug 12, 2026.
10-K for FY2025, filed Feb 20, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells Galafold, an oral medicine for people with Fabry disease, alongside Pombiliti + Opfolda, a two-part treatment for adults with late-onset Pompe disease.
10-K for FY2025, filed Feb 20, 2026We are a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for…View ↗
Commercial success in Fabry disease. For the year ended December 31, 2025, Galafold® revenue was $521.7 million of consolidated revenue…View ↗
We have leveraged our biologics capabilities to develop Pombiliti® + Opfolda®, a novel two-component treatment paradigm for Pompe disease.…View ↗
How Did They Make Money?
Amicus sells medicines to distributors and pharmacies when they receive the products; government authorities are often the ultimate payers.
10-K for FY2025, filed Feb 20, 2026
$634.2M
-
10-K for FY2025, filed Feb 21, 2026
$634.2M ↗
Who Were Their Customers?
Orders for the medicines generally come from distributors and pharmacies, while a government authority is often the ultimate payer.
10-K for FY2025, filed Feb 20, 2026The Company has recorded revenue on sales where its products are available either on a commercial basis or through a reimbursed early…View ↗
10-K for FY2025, filed Feb 20, 2026
The Company has recorded revenue on sales where its products are available either on a commercial basis or through a reimbursed early…View ↗
Did Revenues Turn Into Profits?
Not on paper. It lost $27.1M in FY2025, but brought in more cash than it spent: $29.8M of free cash flow.
10-K for FY2025, filed Feb 21, 2026
$32.8MView ↗
10-K for FY2025, filed Feb 21, 2026
−$27.1MView ↗
10-K for FY2025, filed Feb 21, 2026
$29.8MView ↗
How Were They Changing?
-
Apr 27, 2026
BioMarin completed its acquisition of Amicus
Amicus became a wholly owned subsidiary, and it notified Nasdaq that trading would be halted and shares removed from listing.
Sources
8-K, filed Apr 27, 2026
As a result of the consummation of the Merger, there was a change in control of the Company, and the Company became a wholly owned…View ↗
-
Apr 23, 2026
France cleared the merger's final regulatory condition
Only conditions tied to closing remained before completion.
Sources
8-K, filed Apr 23, 2026
On April 23, 2026, the Ministry of Economics and Finance in France granted clearance for the Merger under the French foreign direct…View ↗
Grew. Revenue grew 2.1x in 4 years, from $305.5M in FY2021 to $634.2M in FY2025, about 20% a year.
Pompe treatment reaches market
The earlier report described the Pompe treatment as under regulatory review; the latest lists Pombiliti + Opfolda among its marketed therapies.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 20, 2026We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare…View ↗
Added a kidney-disease candidate
The earlier report described its portfolio around Fabry and Pompe; the latest also describes United States commercialization rights to a kidney-disease candidate.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 20, 2026We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare…View ↗
Who Did They Compete With?
Competes with Sanofi, Takeda, Chiesi, Idorsia, Sangamo, Bayer, Maze/Shionogi, Travere, and Vertex
10-K for FY2025, filed Feb 20, 2026SanofiView ↗
Loading...
